m6A mRNA Methylation Regulates Human β-Cell Biology in Physiological States and in Type 2 Diabetes.
Dario F De JesusZijie ZhangSevim KahramanNatalie K BrownMengjie ChenJiang HuManoj K GuptaChuan HeRohit N KulkarniPublished in: Nature metabolism (2019)
The regulation of islet cell biology is critical for glucose homeostasis1.N6 -methyladenosine (m6A) is the most abundant internal messenger RNA (mRNA) modification in mammals2. Here we report that the m6A landscape segregates human type 2 diabetes (T2D) islets from controls significantly better than the transcriptome and that m6A is vital for β-cell biology. m6A-sequencing in human T2D islets reveals several hypomethylated transcripts involved in cell-cycle progression, insulin secretion, and the Insulin/IGF1-AKT-PDX1 pathway. Depletion of m6A levels in EndoC-βH1 induces cell-cycle arrest and impairs insulin secretion by decreasing AKT phosphorylation and PDX1 protein levels. β-cell specific Mettl14 knock-out mice, which display reduced m6A levels, mimic the islet phenotype in human T2D with early diabetes onset and mortality due to decreased β-cell proliferation and insulin degranulation. Our data underscore the significance of RNA methylation in regulating human β-cell biology, and provide a rationale for potential therapeutic targeting of m6A modulators to preserve β-cell survival and function in diabetes.
Keyphrases
- type diabetes
- single cell
- endothelial cells
- cell proliferation
- cell cycle
- glycemic control
- cell therapy
- induced pluripotent stem cells
- cardiovascular disease
- pluripotent stem cells
- stem cells
- dna methylation
- insulin resistance
- signaling pathway
- genome wide
- clinical trial
- small molecule
- risk factors
- blood pressure
- protein kinase
- bone marrow
- nucleic acid
- amino acid
- data analysis